NFE2L2 and multiple sclerosis: Based on (1) the well-established effect of skin allergens on the activation of Nrf2 [8,18], (2) experimental evidence highlighting Nrf2 as an attractive molecular target in the context of AD [5,6] and (3) the recent approval of the skin allergen DMF for the management of relapsing forms of multiple sclerosis [12], we were led to the innovative hypothesis that DMF and other unexplored skin allergens could have a preventive and/or therapeutic role in AD.